Vice President, Pharmaceutical Research and Development
Dr. Johnston joined Delcath in October, 2010. Previously he was Principal Research Scientist in the Translational Medicine group at Pfizer, Inc. In this role, he identified and validated pharmacodynamic and patient selection biomarkers for preclinical and clinical assets and guided clinical development and asset differentiation. Dr. Johnston also served as Chair of the Oncology Early Biomarker Strategy Team at Pfizer. Prior to joining Pfizer, he was a Senior Research Scientist for Wyeth Pharmaceuticals Women’s Health Research group, where he was a project team leader for small molecule drug development projects. He earned his PhD at the Johns Hopkins University Bloomberg School of Public Health and completed his postdoctoral training at the School of Molecular Biosciences at Washington State University.